NANOG and cervical cancer: This novel finding in MDBMSCC is consistent with previous studies reporting on cytoplasmic expression of NANOG in cervical cancer (38) and SALL4 in breast cancer (39) cells, inferring cytoplasmic expression as a predictor of poor prognosis (39).